Table 3.

Biodistribution of EpCAM-targeted immunoliposomes (SIL-Dox) and nontargeted liposomes (SL-Dox) loaded with doxorubicin in mice bearing SW2 tumor xenografts

TissueSIL-Dox (%ID/g)
SL-Dox (%ID/g)
24 h48 h24 h48 h
Blood11.8 ± 1.7*1.6 ± 0.512.2 ± 0.92.6 ± 0.4
Liver14.1 ± 0.614.5 ± 1.112.0 ± 1.314.7 ± 1.9
Spleen19.3 ± 2.222.7 ± 2.118.3 ± 1.622.0 ± 1.6
Heart2.4 ± 0.92.6 ± 0.41.5 ± 0.11.7 ± 0.4
Lung2.5 ± 0.81.8 ± 0.61.4 ± 0.21.7 ± 0.3
Kidney6.1 ± 1.410.3 ± 1.26.4 ± 1.59.1 ± 1.1
Tumor13.0 ± 0.515.0 ± 1.07.7 ± 0.77.1 ± 1.7
  • * Values were determined after i.v. injection of [3H]CHE-labeled liposomes. Data represent the mean %ID/g tissue ± SD (n = 3 mice per time point).

  • P < 0.005, compared with SL-Dox. Statistical significance of the difference between SIL-Dox and SL-Dox was evaluated with a two-tailed, unpaired Student's t test.